Psyched Wellness and the National Research Council of Canada Announce Preliminary Data from Studies of Neuroprotective Properties of AME-1 Post published:March 24, 2022 Post category:Press Release
Psyched Wellness Announces Key Findings from the 90-Day Oral Toxicity Study on AME-1 Post published:February 15, 2022 Post category:Press Release
Psyched Wellness Announces Additional Positive Results from the 14-day Oral Toxicity Study of AME-1 Post published:February 3, 2022 Post category:Press Release
Psyched Wellness Announces Launch of New Logo, Branding, and Website, Prepares to Release Industry-First Amanita Muscaria Tincture Post published:February 1, 2022 Post category:Press Release
Psyched Wellness Provides Update on Anti-Inflammatory Study with the National Research Council of Canada Post published:January 26, 2022 Post category:Press Release
Psyched Wellness Announces Path to Market for AME-1-derived Products in the USA Post published:December 16, 2021 Post category:Press Release
Psyched Wellness Hires Del Mahabadi as Digital Marketing Consultant to Drive AME-1 Product Launch Post published:December 14, 2021 Post category:Press Release
Psyched Wellness Presents AME-1 to Health Canada in Pre-Submission Meeting Post published:December 1, 2021 Post category:Press Release
Psyched Wellness Announces That the Amanita Muscaria Mushroom Has Been Successfully Added to the Natural Health Products Ingredients Database (NHPID) of Canada Post published:November 3, 2021 Post category:Press Release
Psyched Wellness Announces Preliminary Data Showing Potential New Functional Property and Health Benefit of Amanita Muscaria Mushroom (AME-1) To Inhibit Human Mast Cell Activation Post published:October 19, 2021 Post category:Press Release